Bladder cancer
New hope for patients progressing after prior treatment for mUCa

Tristan (75 years old)

Tristan, 75 years old and often distracted, plays the trumpet. When he plays in the brass band, he often suddenly stops because he sees a bird flying over or a car passing by. A major challenge for the conductor.

He was diagnosed with high-grade urothelial muscle-invasive bladder cancer (MIBC) T2N0M0 and underwent neoadjuvant gemcitabine + cisplatin followed by radical chemoradiotherapy. Three months after radical chemoradiotherapy, a CT scan revealed multiple retroperitoneal and intrathoracic lymph node metastases. He started pembrolizumab 7 months ago and presents himself again today.

Assessment summary:

  • ECOG PS: 1
  • Haemoglobin: 12.5 g/dl
  • Peripheral neuropathy: grade 1 due to prior cisplatin
  • No hearing impairment
  • GFR: 45 ml/min
  • CT scan reveals new and enlarging lymph node lesions
  • FGFR2/3 mutation status in diagnostic biopsy specimen: wild type

Which of the following treatment options would you choose for this patient?